
	Where results make sense

Topic: Aventis

Related Topics

Hoechst

Alstom

List of European companies

Eli Lilly and Company

Thomson

Matra

TUI AG

MAN (company)

Cap Gemini

ThyssenKrupp AG

Bayer AG

Bayer

List of Belgian companies

Allianz AG

AgustaWestland

In the News (Mon 28 May 12)

EXECUTIVE POWER

Iran

ANALYSIS

Pakistan

Family compact

	Aventis - Wikipedia, the free encyclopedia
		The Aventis Prizes for Science Books, which celebrate the very best in popular science writing for adults and children, have grown to be one of the world's most prestigious non-fiction literary prizes.
		The Aventis Prizes are managed by the Royal Society, the UK national academy of science, and the Aventis Foundation, a German charitable trust established in 1996 as the Hoechst Foundation with an endowment of €50 million.
		In 2000 the foundation was renamed the Aventis Foundation subsequent to the 1999 merger of Hoechst and Rhône-Poulenc.
	en.wikipedia.org /wiki/Aventis (192 words)

	CorpWatch : Aventis: Global Compact Violator
		Aventis was to require farmers to sign a licensing agreement stating that the grower was aware of and would adhere to these two requirements.
		Aventis failed miserably in applying this guideline despite the fact that the company was legally required to inform growers that StarLink corn cannot be sold into international or human food markets and that a 660 foot buffer zone must be planted.
		Aventis should be suspended from the Global Compact until their behavior comes in line with its principles.
	www.corpwatch.org /article.php?id=621 (1754 words)

	Aventis (Site not responding. Last check: 2007-11-06)
		Aventis Limited is not responsible for third party content or the consequences of your use thereof.
		Aventis Limited does not endorse, and is not responsible for, the accuracy or completeness of any information or opinions set forth in such materials.
		Aventis Limited shall be free to use any information, including but not limited to ideas, concepts, know-how or techniques, contained in such communication for any purpose, without compensation to you and without identifying the source.
	www.aventispharma.com.pk /terms.htm (858 words)

	Sanofi-Aventis - Wikipedia, the free encyclopedia
		Initially, Aventis rejected the bid because it offered inferior value based on the company's share value.
		French government, desiring a local merger solution, put heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis after it became known that Novartis, a Swiss pharmaceutical company, was in the running.
		Aventis was formed in 1999 when Rhône-Poulenc S.A. merged with Hoechst Marion Roussel, in turn formed merging Hoechst AG with Roussel and Marion Merrell Dow.
	en.wikipedia.org /wiki/Sanofi-Aventis (496 words)

	Aventis Reports First-Quarter Results for 2004
		Aventis advanced its regulatory submissions program in the first quarter, submitting the blockbuster oncology agent Taxotere for U.S. and EU approval in March for the treatment of early stage breast cancer as well as for hormone refractory prostate cancer earlier this year.
		Aventis remains committed to moving the reissuance process forward and continues to believe that, if the application is ultimately approved, the '618 patent could be reissued in an amended version prior to year-end 2004.
		Aventis net debt at the end of March 2004 was euro 2.935 billion, reflecting a decrease of euro 1.025 billion compared to the end of 2003.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=109&STORY=/www/story/04-29-2004/0002163321&EDATE= (3757 words)

	LifeSpan Biosciences - Aventis
		Aventis joins Pfizer, Merck and Co., Bristol-Myers Squibb, Novartis Research Foundation and Sanofi-Synthelabo in using LifeSpan's database to identify and prioritize potential drug targets from among the many candidates that have been identified by the genomics revolution.
		Aventis Pharma has its corporate headquarters in Frankfurt, Germany, and includes Aventis Pasteur, a world leader in vaccines based in Lyon, France, and Aventis Behring, a world leader in therapeutic proteins headquartered in King of Prussia, Pennsylvania.
		Aventis was launched in December 1999 through the merger of Hoechst AG of Germany and Rhone-Poulenc SA of France.
	www.lsbio.com /about/newsroom/pr_aventis.aspx (722 words)

	Miller: Aventis Signs Formal Agreement to Mitigate Losses from StarLink Corn (Binding contract details measures to ... (Site not responding. Last check: 2007-11-06)
		Aventis has said the goal of its "StarLink Enhanced Stewardship" and StarLink Logistics plans is to completely segregate StarLink corn from other grain and to move StarLink corn and commingled corn to approved sites and approved uses such as animal feed and certain industrial uses.
		Aventis' obligations set out in Exhibits A, B, and C and in subsection (b) are obligations pursuant to this Agreement and are enforceable by the States.
		Aventis has assured the States that it has access to assets necessary to satisfy its obligations pursuant to Exhibits A, B, and C and pursuant to this Agreement.
	www.state.ia.us /government/ag/StarLink_binding_agt_rel.htm (1516 words)

	MicroStrategy - Aventis Pasteur: MicroStrategy Customer Success Story
		Aventis Pasteur is successfully using MicroStrategy in the United States to anchor its mission critical business intelligence applications across the enterprise.
		Aventis Pasteur, a world leader in vaccines with the broadest range of products, produces more than one billion doses of vaccines every year to immunize 400 million people around the world.
		Aventis Pasteur SA is the largest company in the world devoted entirely to vaccines.
	www.microstrategy.com /Customers/Successes/aventis.asp (354 words)

	Aventis Ends Peptor Collaboration (Site not responding. Last check: 2007-11-06)
		Aventis has returned development rights for DiaPep277 for type 1diabetes to DeveloGen and ended its collaborative agreement on that compound with DeveloGen.
		At this point, Aventis has determined the development project no longer meets its corporate business priority criteria for progression, and has decided to focus on other compounds in its diabetes pipeline.
		Aventis is dedicated to treating and preventing disease by discovering and developing innovative prescription drugs and human vaccines.
	www.pharma-lexicon.com /medicalnews.php?newsid=8374 (321 words)

	ZoomInfo Web Summary: Aventis SA
		Aventis is one of the world's leading pharmaceutical companies and is dedicated to improving life through the discovery and development of innovative pharmaceutical products.
		Aventis develops and markets products and services that improve the quality of people's lives while creating value for customers, employees, shareholders and society at large.
		Aventis is a global pharmaceutical group that discovers, develops, manufactures and markets branded prescription drugs and human vaccines to protect and improve the health of patients around the world.
	www.zoominfo.com /Search/CompanyDetail.aspx?CompanyID=3555642&cs=QENkE6e4 (602 words)

	Aventis agrees to sale (Site not responding. Last check: 2007-11-06)
		Aventis, the parent company of Aventis Pasteur in Swiftwater, accepted a bid for 55.2 billion euros or $65.4 billion from French drug-maker Sanofi-Synthelabo.
		Aventis Pasteur is routinely praised by community leaders for providing high-paying, high-tech jobs and has added about 400 jobs to the area over the past four years.
		Aventis was created in 1998 by the merger of Hoechst of Germany and Rhone-Poulenc of France.
	www.pennsnortheast.com /i_hot_news/050304.shtm (423 words)

	BBC NEWS \| Business \| Aventis and Sanofi set for merger (Site not responding. Last check: 2007-11-06)
		Aventis has fought the hostile takeover since rejecting it in February.
		France's Prime Minister Jean-Pierre Raffarin said that: "The choice of a merger between Sanofi and Aventis will allow the preservation of decision centres and jobs in France and Europe, and is in line with a strategic interest".
		The synergies are persuasive; Aventis has a powerful presence in the huge US market, but a relatively weak inventory of new drugs -- called a drugs pipeline in the pharmaceutical industry -- while Sanofi is the opposite; a full pipeline, but a poor presence in the US.
	news.bbc.co.uk /1/hi/business/3658639.stm (412 words)

	Jones Day - Experience - Vitamin Antitrust Litigation
		While Aventis and five other manufacturers resolved class action claims against them in November of 1999, hundreds of the companies’ customers opted out of the class settlement and pursued individual actions against the vitamin defendants.
		Aventis resolved all of those claims prior to trial, which was scheduled for the spring of 2003.
		The $375 million settlement between Aventis and certain of its codefendants, the states’ Attorneys General, and private class action plaintiffs has been finally approved by each of the participating states.
	www.jonesday.com /experience/experience_detail.aspx?exid=10998503 (303 words)

	Aventis Bio-Services Annouces Acquisition Of 47 Plasma Donation Centers (Site not responding. Last check: 2007-11-06)
		Aventis Bio-Services, Inc., is the world's largest, fully integrated plasma collection company with donation centers, laboratories and logistics centers in the United States and Europe.
		Aventis Behring, a $1.5 billion world leader in the plasma protein industry, provides a wide range of innovative, high quality therapies and unique support services to patients worldwide.
		Aventis Behring is dedicated to the research and development of proteins from human blood plasma and emerging technologies.
	www.zlbbehring.com /zb/n35241pr34291/AventisBioServicesAn.htm (469 words)

	Aventis Pharmaceuticals, Inc.
		Aventis Pharmaceuticals, Inc. is a branch of Aventis.
		From the start, Aventis Pharmaceuticals will have the resources to become a leader in today's highly competitive pharmaceutical industry: one of the world's largest research and development budgets, commercial strengths in all of the world's major markets, experienced international management and an outstanding workforce.
		Celera Genomics Group-an Applera Corp. Business Aventis is investigating the use of Cathepsin S inhibitors in a number of therapeutic areas related to inflammation and autoimmune disease.
	www.biospace.com /company_profile.aspx?CompanyID=136704 (460 words)

	Aventis and HHS Enter Into Pandemic Influenza Vaccine Agreement, USA (Site not responding. Last check: 2007-11-06)
		Aventis Pasteur, the human vaccines business of Aventis, part of the sanofi-aventis Group, has agreed to produce two million doses of bulk vaccine containing the potential pandemic virus strain.
		“As the world’s largest supplier of influenza vaccine, Aventis Pasteur is committed to partnering with the government to develop a safe and effective vaccine in preparation for a possible influenza pandemic,” said David J. Williams, chairman and chief executive officer of Aventis Pasteur.
		Aventis Pasteur, the vaccines business of Aventis, part of the sanofi-aventis Group, produced 1.4 billion doses of vaccine in 2003, making it possible to protect 500 million people across the globe, which is about 1.4 million per day.
	www.medicalnewstoday.com /medicalnews.php?newsid=13891 (719 words)

	Aventis Deal Changes Field in Europe
		Aventis had hoped to do a friendly deal with Swiss drug giant Novartis (NVS:NYSE - news - research), which happens to be the product of the 1996 merger of Ciba-Geigy and Sandoz.
		Aventis, itself, is the 1999 creation of a cross-border marriage between France's Rhone-Poulenc and Germany's Hoechst, both of which acquired several other drug companies over the years.
		For the 12-month period ended April 22, Aventis' ADRs are up 69% compared to the 25% gain of the SandP 500 and the 8.6% gain by the Amex Pharmaceutical Index of 15 large U.S. companies.
	www.thestreet.com /stocks/robertsteyer/10156292.html (318 words)

	Bayer Agrees to Acquire Aventis CropScience (Site not responding. Last check: 2007-11-06)
		For Aventis, the expected decrease in the net debt -- through the proceeds from the divestment as well as the deconsolidation of debt associated with CropScience -- would mean additional flexibility for the future development of its pharmaceutical business.
		Aventis CropScience is a major crop protection company focusing on researching, developing and marketing innovative solutions that meet the needs of today's farming: healthy crops, increased yields, improved crop and food quality.
		Aventis (NYSE: AVE - news) is dedicated to improving life through the discovery and development of innovative products.
	www.biotech-info.net /aventis_bayer.html (428 words)

	Sanofi-Synthelabo lands Aventis for $64 billion - Apr. 26, 2004
		Sanofi-Synthelabo, which had launched a hostile bid for Aventis in January, was pressured to raise its bid by French government officials, who were worried that Aventis would otherwise be bought by Swiss drugmaker Novartis, and that Sanofi-Synthelabo itself could become a takeover target without a deal.
		Aventis shares have recently traded at a substantial premium to Sanofi's original offer as investors bet Novartis would trump it or Sanofi would put more cash on the table.
		Aventis' leading drugs are allergy pill Allegra, cancer treatment Taxotere and anti-blood clotting drug Lovenox, while Sanofi's top sellers include anti-stroke medicine Plavix, sleeping pill Ambien and cancer therapy Eloxatin.
	money.cnn.com /2004/04/26/news/international/aventis_sanofi (817 words)

	Proposed Relocation of Aventis' Headquarters From Strasbourg to Paris
		Since April 26, 2004, when Sanofi-Synthelabo and Aventis agreed to create sanofi-aventis, it has been confirmed that the headquarters of the new sanofi-aventis Group is to be located in Paris.
		Aventis employs a staff of 220 in Schiltigheim, as well as 60 service providers.
		In accordance with the Group's employment policy, a series of measures intended to facilitate staff mobility will be implemented with the aim of redeploying all employees.
	www.medicalnewstoday.com /medicalnews.php?newsid=16953 (487 words)

	Novartis considers bid for Aventis - International Business - MSNBC.com (Site not responding. Last check: 2007-11-06)
		Aventis shares rose three percent to 64.35 euros, a nine percent premium to Sanofi's bid.
		Booty currently estimates there is a 10 percent chance of Aventis remaining as a standalone company, a 30 percent chance of a white knight bidder taking it over and a 60 percent chance of Sanofi prevailing with a higher offer.
		The firm has told investors to keep their nerve and hold on to their shares, as it seeks alternatives to what it said was a "ridiculous" bid from Sanofi, a smaller rival.
	msnbc.msn.com /id/4514997 (825 words)

	Aventis Prizes for Science Books - Media Releases (Site not responding. Last check: 2007-11-06)
		The Aventis Prizes for Science Books are managed by The Royal Society, the UK national academy of science, and generously supported by the Aventis Foundation, a German charitable trust established by a predecessor of sanofi-aventis, a world leader in pharmaceuticals.
		The Aventis Foundation (www.aventis-foundation.org) is a German charitable trust established by a predecessor of sanofi-aventis, a world leader in pharmaceuticals.
		The Aventis Foundation serves to promote music, theatre, art and literature, projects in the social and political arena with a focus on healthcare, as well as science, research and higher education.
	www.aventisprizes.com /press_media_12may2005jun.htm (1067 words)

	bayer's aventis cropscience - public enemy no. 1 in the UK
		Aventis must now admit it is at fault and accept the full consequences of its actions.
		Aventis ``didn`t live up to its side of the bargain,`` said Jim Aidala, an official from the EPA, which approved Starlink only for animal feeds or industrial use because the agency couldn`t rule out the possibility that humans would be allergic to it.
		Aventis, a French-German conglomerate formed from a merger of two companies in December, was growing the canola on a site at Yells Road, Moorak, a few kilometres south of Mount Gambier, the paper said.
	members.tripod.com /~ngin/agrevodiary.htm (6559 words)

	Aventis accepts Sanofi's $65-bn bid- The Times of India (Site not responding. Last check: 2007-11-06)
		The higher offer represented a shift for both Sanofi, which had refused to alter its $60 billion bid for Aventis, made in January, and for Aventis, which had insisted that it would be a stronger company if it did not combine with Sanofi.
		All 16 members of Aventis' board were said to have voted to approve the deal, after a seven-hour board meeting.
		Separately, Sanofi's bid for Aventis may be approved by the EC, according to one person close to the situation.
	timesofindia.indiatimes.com /articleshow/641036.cms (304 words)

Try your search on: Qwika (all wikis)